Clinical trial NCT01638104: ANX-042 Healthy Volunteer Dose Escalation Study
Official title: ANX-042 Healthy Volunteer Dose Escalation Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Anexon, Incorporated
name: Celerion
First posted: 2012-07-11
Enrollment: 30
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to investigate the safety and tolerability of ANX-042 when administered by continuous intravenous (IV) infusion in healthy volunteers.

Detailed description: Each participant received a total of two, approximately 12-hour continuous infusions of ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between treatments.

This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.

Eligibility criteria: Inclusion Criteria:

* Men or women of non-reproductive potential (WNRP)

  * Men must be willing to use effective contraception and not donate sperm for up to 90 days after the final dose of study drug
  * Women must be of non-reproductive potential defined as a history of surgical sterilization or postmenopausal status (that is, greater than ( \>) 50 years of age with \>12 months amenorrhea while not using hormonal contraceptives or \>50 years of age with 6-12 months of amenorrhea and follicle stimulating hormone (FSH) level \>40 international unit/liter (IU/L)
* Good health status, physically active without cardio-respiratory limitations and minimal concomitant medications as determined by medical history and physical examination
* Able and willing to comply with study procedures, including controlled sodium (Na) intake and restriction of caffeine and tobacco product
* Have given written informed consent prior to the initiation of any study procedures

Exclusion Criteria:

* History of cardiovascular disease, unexplained syncope, postural tachycardia syndrome or frequent postural hypotension
* History or current evidence of respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders that would constitute a risk when taking the study medication or interfere with the interpretation of data
* Clinically significantly abnormal clinical laboratory results (including Hepatitis B, Hepatitis C and Human Immunodeficiency Virus (HIV) serology) or physical examination results (confirmed by repeat measurement, if appropriate) that, in the opinion of the Investigator, would constitute a risk when taking the study medication or interfere with the interpretation of data
* Abnormal orthostatic Blood Pressure/Heart Rate (BP/HR) response at screening as defined by:

  * Systolic Blood Pressure (BP) decrease \>20 millimeters of mercury (mmHg)
  * Diastolic BP decrease \>10 mmHg, or
  * HR increase \>25 beats per minute (bpm) and to a level above 100 bpm
* One or two supine values must be obtained between 8 and 10 minutes of supine rest. One or two upright values must be obtained between 3 and 5 minutes upright with the arm passively supported to maintain the brachial artery at heart level
* Abnormal 12-lead electrocardiogram (ECG) that interferes with proper measurement of QT-interval or, in the opinion of the Investigator, increases the risk of participating in the study
* Elevated BP (\>140/90 mmHg) in any posture, confirmed by repeat measurement
* Current use (within 7 days of first dosing) or expected need for concomitant medications with hemodynamic effects including: non-steroidal anti-inflammatory drugs (NSAIDS), decongestants, BP medications, diuretics, monoamine oxidase inhibitors, norepinephrine uptake inhibitors (for example, attention-deficit disorder medications, anti-depressants) and erectile dysfunction medications. Medications with low likelihood of hemodynamic or renal effects are permitted (for example, acetaminophen, vitamins, stable thyroid hormone, gastritis therapies, antihistamines, topical medications, et cetera) after approval by the Investigator
* Evidence of current or recent use of known drugs of abuse and/or positive findings on urinary drug screening
* History of an average weekly alcohol intake that exceeds 21 units per week (1 unit equal to (=) 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption for the duration of the study
* History of regular smoking of \>5 cigarettes, cigars and/or pipe bowls of tobacco per day
* Known allergies to nesiritide (Natrecor)
* History of blood donation of \>500 mL within one month, or plasma donation within 14 days, of first dosing
* Are currently enrolled in, or have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* Are investigator site personnel directly affiliated with this study or their immediate family members. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
* Are Lilly or Anexon employees or employees of any third-party organization (TPO) involved with the study that require exclusion of their employees

Primary outcomes:
measure: Number of participants with one or more drug-related adverse events (AEs) or any serious AEs
timeFrame: 0 to 4 weeks
Secondary outcomes:
measure: Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of ANX-042
timeFrame: 0 to 24 hours post dose
measure: Pharmacokinetics: Steady state plasma concentration of ANX-042
timeFrame: 12 hours post dose
Other outcomes:
Locations:
city: Lincoln
country: United States
facility: Celerion
state: Nebraska
Study officials:
affiliation: Anexon, Incorporated
name: Email: Anexon@Choruspharma.com
role: STUDY_DIRECTOR
References: